<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03671941</url>
  </required_header>
  <id_info>
    <org_study_id>180BE18003</org_study_id>
    <nct_id>NCT03671941</nct_id>
  </id_info>
  <brief_title>Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-357 and D578 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Crossover Study to Evaluate Pharmacokinetic Profiles and Safety/Tolerability of CKD-357 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, single dose, crossover study to evaluate pharmacokinetic profiles
      and safety/tolerability of CKD-357 in healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To healthy subjects of thirty(30), following treatments are administered dosing in each
      period and wash-out period is a minimum of 7 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2018</start_date>
  <completion_date type="Actual">June 18, 2018</completion_date>
  <primary_completion_date type="Actual">June 4, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of Ticagrelor</measure>
    <time_frame>Pre-dose(0 hour), post-dose 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Area under the plasma concentration of Ticagrelor versus time curve from time zero to time of last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Ticagrelor</measure>
    <time_frame>Pre-dose(0 hour), post-dose 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Maximum plasma concentration of Ticagrelor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Ticagrelor</measure>
    <time_frame>Pre-dose(0 hour), post-dose 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Area under the plasma concentration of Ticagrelor versus time curve from time zero to time infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Ticagrelor</measure>
    <time_frame>Pre-dose(0 hour), post-dose 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Time to maximum concentration of of Ticagrelor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Ticagrelor</measure>
    <time_frame>Pre-dose(0 hour), post-dose 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Apparent terminal half-life of Ticagrelor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Ticagrelor</measure>
    <time_frame>Pre-dose(0 hour), post-dose 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Total body clearance of Ticagrelor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Ticagrelor</measure>
    <time_frame>Pre-dose(0 hour), post-dose 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Apparent volume of distribution of Ticagrelor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt of AR-C124910XX</measure>
    <time_frame>Pre-dose(0 hour), post-dose 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Area under the plasma concentration of AR-C124910XX versus time curve from time zero to time of last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of AR-C124910XX</measure>
    <time_frame>Pre-dose(0 hour), post-dose 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Maximum plasma concentration of AR-C124910XX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of AR-C124910XX</measure>
    <time_frame>Pre-dose(0 hour), post-dose 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Area under the plasma concentration of AR-C124910XX versus time curve from time zero to time infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of AR-C124910XX</measure>
    <time_frame>Pre-dose(0 hour), post-dose 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Time to maximum concentration of AR-C124910XX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of AR-C124910XX</measure>
    <time_frame>Pre-dose(0 hour), post-dose 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Apparent terminal half-life of AR-C124910XX</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>D578 Tab. 1T</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-357 Tab. 1T</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D578</intervention_name>
    <description>D578 Tab.1T single oral administration under fasting condition</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Ticagrelor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-357</intervention_name>
    <description>CKD-357 Tab.1T single oral administration under fasting condition</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Novel salts of Ticagrelor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        [Inclusion Criteria]

          1. A healthy adult whose age is over 19 years old when visiting for initial screening
             test

          2. Body mass index(BMI) between 17.5~30.5 kg/m^2 and the body weight must be over 55kg
             (Body mass index (BMI) = weight (kg) / height (m)^2)

          3. A person with no congenital or chronic disease in three years, no history of symptoms
             in internal treatment, or no knowledge in the area

          4. Due to the special characteristics of drugs, the participators must be qualified to do
             the clinical screening after examined through hematology test and blood chemistry
             analysis, urinary test, viral/bacterial test, the electrocardiogram (ECG), and etc.

          5. The participants must be volunteered and sign in an informed consent document proven
             by Chonbuk National University IRB before joining a study to show that he was given
             informed the purpose of tests and the special characteristics of drugs.

          6. The participants must have an ability and willingness to participate throughout the
             entire trials

        [Exclusion Criteria]

          1. A person who had a history or symptoms of clinically aware of blood, kidney, internal
             secretion, respiratory, gastrointestinal, urinary system, cardiovascular, liver,
             mental, nervous, or allergic(except subclinical seasonal allergies that is not treated
             at injection) disease.

          2. Who had a history of gastrointestinal related disease which can be affected the drug
             absorption (esophageal achalasia, esophagostenosis, esophageal disease, or Crohn's
             disease) or surgeries (except a simple appendectomy or herniotomy)

          3. Who had following results after examination

             a. ALT or AST &gt; twice higher than normal value

          4. Who constantly intake 210 g/week of alcohol within 6 months of the screening. (a cup
             of beer (5%) (250 mL) = 10 g, a shot of soju (20%) (50mL) = 8 g, a glass of wine (!2%)
             (125 mL) = 12g)

          5. Who participated other clinical test or took testing bioequivalence drugs in 3 months
             before the first clinical drug trial.

          6. Whose blood pressure &lt; 100 or ≥140(systolic blood pressure) or &lt; 70 or ≥ 90(diastolic
             blood pressure)

          7. Who had a medical history of alcohol and drug abuses.

          8. Who had taken a drug that has a control of metabolic rate (activation or inhibition)
             in 30 days before the first taking of clinical testing durg.

          9. Who smokes more than 20 cigarettes per day within 6 months of the screening

         10. Who took prescribed drugs or over-the-counter drugs in 10 days before taking of very
             first clinical testing drug.

         11. Who participated in whole blood donation in 2 months before the first taking of
             clinical testing drugs or platelet donations in 1 month before the first taking to
             clinical testing drugs

         12. Who has a potent to increase a danger by participating in the clinical trials or sho
             can interrupt interpreting test results by having serious or chronic medical and
             mental status or having issues in results of the screening examination.

         13. Who has a history of an extreme sensitivity of composition of the drug

         14. Who has hemorrhagic tendency(recently trauma, recently surgery, coagulation disorder,
             recently gastrointestinal bleeding)and are scheduled for surgery within one month

         15. Who has a potent to increase a danger of beat heart slowly like symptom of bradycardia
             and dyspnea

         16. Who had a medical history of hyperuricacidemia and gouty arthritis

         17. Who has a Pregnant or potentially pregnant.

         18. A person who is not determined unsuitable to participate in this test by the
             researchers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Ho Jang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 13, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>September 18, 2018</last_update_submitted>
  <last_update_submitted_qc>September 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

